| Breaking the therapeutic ceiling in drug development in ulcerative colitis D Alsoud, B Verstockt, C Fiocchi, S Vermeire The lancet Gastroenterology & hepatology 6 (7), 589-595, 2021 | 82 | 2021 |
| Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? D Alsoud, S Vermeire, B Verstockt Current opinion in pharmacology 55, 17-30, 2020 | 31 | 2020 |
| Tailoring multi-omics to inflammatory bowel diseases: all for one and one for all P Sudhakar, D Alsoud, J Wellens, S Verstockt, K Arnauts, B Verstockt, ... Journal of Crohn's and Colitis 16 (8), 1306-1320, 2022 | 17 | 2022 |
| Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis D Alsoud, G De Hertogh, G Compernolle, S Tops, J Sabino, M Ferrante, ... Journal of Crohn's and Colitis 16 (10), 1562–1570, 2022 | 16 | 2022 |
| Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises D Alsoud, S Vermeire, B Verstockt Current Research in Pharmacology and Drug Discovery 3, 100089, 2022 | 11 | 2022 |
| Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center A Moens, D Alsoud, B Verstockt, J Sabino, M Ferrante, S Vermeire European Journal of Gastroenterology & Hepatology 34 (10), 1015-1020, 2022 | 9 | 2022 |
| Translating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD A Moens, B Verstockt, D Alsoud, J Sabino, M Ferrante, S Vermeire Inflammatory Bowel Diseases 28 (8), 1135-1142, 2022 | 9 | 2022 |
| The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases W Kantasiripitak, B Verstockt, D Alsoud, T Lobaton, D Thomas, A Gils, ... British Journal of Clinical Pharmacology 87 (10), 3776-3789, 2021 | 9 | 2021 |
| Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis B Verstockt, V Volk, C Jaeckel, D Alsoud, J Sabino, S Nikolaus, A Outtier, ... Alimentary Pharmacology & Therapeutics 56 (2), 282-291, 2022 | 8 | 2022 |
| immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era. D Alsoud, B Verstockt, S Vermeire Alimentary Pharmacology & Therapeutics 55 (7), 2022 | 4 | 2022 |
| P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis D Alsoud, G Compernolle, S Tops, J Sabino, M Ferrante, D Thomas, ... Journal of Crohn's and Colitis 16 (Supplement_1), i424-i424, 2022 | 4 | 2022 |
| P401 Tofacitinib tissue exposure correlates with endoscopic outcome B Verstockt, D Alsoud, J van Oostrom, J Smith, J Stylli, S Singh, ... Journal of Crohn's and Colitis 16 (Supplement_1), i394-i395, 2022 | 4 | 2022 |
| Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease D Alsoud, S Verstockt, J Sabino, M Ferrante, N Noor, B Verstockt, ... Journal Of Crohns & Colitis 15, S168-S168, 2021 | 4 | 2021 |
| Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study D Alsoud, J Sabino, D Franchimont, A Cremer, J Busschaert, F D’Heygere, ... Inflammatory Bowel Diseases, izad315, 2024 | 3 | 2024 |
| P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease D Alsoud, J Sabino, M Ferrante, S Vermeire, B Verstockt Journal of Crohn's and Colitis 16 (Supplement_1), i427-i428, 2022 | 1 | 2022 |
| Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease D Alsoud, B Van Calster Inflammatory Bowel Diseases 30 (6), 1050-1051, 2024 | | 2024 |
| Reply to: Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease D Famutimi, QA Alayo, P Deepak Inflammatory Bowel Diseases 30 (6), 1052-1052, 2024 | | 2024 |
| Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics D Alsoud, B Verstockt, S Vermeire Inflammatory Bowel Diseases 30 (5), 874-875, 2024 | | 2024 |
| The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn’s Disease D Alsoud, J Ho, B Verstockt Journal of Crohn's and Colitis 17 (10), 1703-1704, 2023 | | 2023 |
| Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis. D Alsoud, J Ho, J Sabino, M Ferrante, S Vermeire, B Verstockt The American Journal of Gastroenterology, 2023 | | 2023 |
